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Abbreviations: 
ADCC: antibody dependent cellular cytotoxicity 
APC: antigen presenting cell 
C3d(g): C3 d(g) fragment of C3 
iC3b: inactivated complement C3b fragment 
CR1: complement receptor type1 
CR2: complement receptor type 2 
CR3: complement receptor type 3 
CR4: complement receptor type 4 
CRIg: complement receptor of the Ig superfamily 
DC: dendritic cell 
HI: heat inactivated 
imDC: immature dendritic cell 
imMDC: immature monocyte-derived dendritic cell 
maMDC: mature monocyte-derived dendritic cell  
MDC: monocyte-derived dendritic cell 
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Abstract 
Dendritic cells (DCs) play a decisive role in immunity; they interact with various 
pathogens via several pattern recognition and different opsonophagocytotic receptors, 
including Fc- and complement-receptors. β2-integrins, including complement receptors CR3 
(CD11b/CD18) and CR4 (CD11c/CD18) participate in many immunological processes, 
especially those involving cell migration, adherence, and phagocytosis. Human monocyte 
derived dendritic cells (MDCs) are known to express CR3 as well as CR4, however possible 
differences regarding the role of these receptors has not been addressed so far. Our aim was to 
explore whether there is a difference between the binding and uptake of various complement-
opsonized microorganisms, mediated by CR3 and CR4. Studying the expression of receptors 
during differentiation of MDCs we found that the appearance of CD11b decreased, whereas 
that of CD11c increased. Interestingly, both receptors were present in the cell membrane in an 
active conformation. Here we demonstrate that ligation of CD11b directs MDCs to enhanced 
phagocytosis, while the maturation of the cells and their inflammatory cytokine production 
are not affected.  Blocking CD11c alone did not change the uptake of opsonized yeast or 
bacteria by MDCs. We confirmed these results using siRNA; namely downregulation of 
CD11b blocked the phagocytosis of microbes while silencing CD11c had no effect on their 
uptake. Our data clearly demonstrate that complement C3-dependent phagocytosis of MDCs 
is mediated mainly by CR3.  
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Introduction 
The complement system is a key element of an efficient immune response. Its  
activation leads to the cleavage of the central complement component, C3, generating C3a 
and different fragments fixed covalently to the activating surface - such as C3b, iC3b, C3c, 
and C3d(g). These activation products are the ligands of various complement receptors, 
namely C3aR, CR1, CR2, CR3, CR4 and CRIg, expressed by a wide variety of immune cells 
(Bajtay et al., 2006; Carrol, 1998; Erdei et al., 2009; Li et al., 2011; Liu and Niu, 2009). The 
most abundant complement receptors present on the surface of neutrophils, monocytes, 
macrophages, NK cells and dendritic cells (DCs) are CR3 (CD11b/CD18) and CR4 
(CD11c/CD18). Both receptors are members of the β2 integrin family, and the heterodimeric 
receptors consist of one α and one β subunit. Integrins mediate important cellular functions, 
like adhesion, especially during the formation of the immunological synapse, transendothelial 
migration of immune cells and interaction with the extracellular matrix. The natural ligand of 
CR3 and CR4 is the inactivated fragment of C3, namely iC3b (Rosen and Law, 1990; Ross 
and Vetvicka, 1993).  One of the most important functions of these complement receptors is 
that they mediate phagocytosis, which results in the clearance of pathogens, apoptotic- and 
tumor cells. Integrin signalling is also exploited by microbial pathogens for entry into host 
cells (Bajtay et al., 2004; Dupuy and Caron, 2008; Oliva et al., 2008). Important functions of 
macrophages and DCs are the processing and presentation of antigens to initiate adaptive 
immunity by the activation of T lymphocytes. These professional antigen presenting cells 
express different phagocytic receptors including FcRs, scavenger receptors, C-type lectins, 
CRIg and integrins.  Among these latter structures CR3 was the first to be demonstrated to 
mediate   phagocytosis (Dupuy and Caron, 2008). In addition CR3 has also been shown to 
play a critical role in antibody dependent cellular cytotoxicity (ADCC) against various targets 
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including different tumors and parasites (Capron and Dessaint, 1985; Gelderman et al., 2004a; 
Gelderman et al., 2004b; van Spriel et al., 2001; van Spriel et al., 2003; Vignali et al., 1990).   
Pathogen microbes entering the body become opsonized by complement proteins, 
mainly by the larger fragments of C3, which help eliminate antigens by the phagocytes, 
including immature dendritic cells (imDCs). CR3 and CR4 are generally thought to mediate 
overlapping functions; however the possible distinctive role of these receptors has not been 
investigated so far.  
The aim of the present work is to reveal whether CR3 and CR4 mediate different 
functions on human monocyte-derived DCs, and to monitor if the expression and function of 
these complement receptors changes during DC maturation. Studying their functions on 
MDCs we clearly demonstrate that CR3 – but not CR4 - plays a key role in the phagocytosis 
of iC3b-opsonized particles. We found that CR3 expression is downregulated on MDCs 
during maturation, in contrast to CR4 which is significantly enhanced in the same time. 
Investigating the effect of the common ligand, iC3b and a CD11b specific antibody we found 
that the phenotype of MDCs did not change significantly after treatment, suggesting that 
CD11b/CD18 transduces signals which affect phagocytosis only.
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 Materials and Methods 
Reagents and antibodies 
For the isolation and culture of cells the following materials were used: Ficoll-Paque 
(Amersham, Uppsala, Sweden), CD14+ Microbeads from Miltenyi Biotec (Bergisch 
Gladbach, Germany), CellGro serum free DC Medium (CellGenix, Germany), recombinant 
human (rHu) IL-4 (R&D systems), rHu GM-CSF (R&D systems). LPS was purchased from 
Sigma (Hungary). Carboxy-fluorescein-succinimide-ester (CFSE) and FITC were obtained 
from Molecular Probes (Invitrogen, USA), saponine from Fluka (Switzerland), iC3b from 
Merck (Germany). 
The following primary and secondary antibodies were used for FACS and confocal 
microscopic analysis:  anti-hu CD4-A647 from SantaCruz (USA), FITC-labeled anti-biotin 
mAb from Sigma (Hungary), streptavidine-Alexa546, streptavidine-Alexa647, streptavidine-
Alexa488, Alexa488 labeled goat-anti-mouse Ig from Molecular Probes (Invitrogen, USA). 
FITC-labeled anti-hu-MHCII, FITC-labeled anti-hu-CD83, FITC-labeled anti-hu-CD86, 
APC-labeled anti-hu CD14 mAb and biotynilated anti-hu CD11b from BD PharMingen 
(USA),  PE conjugated mouse-anti-hu mannose receptor (mIgG1, 3.29B1.10) from 
Immunotech (France), biotinilated anti-hu CD40 from Serotec (UK), monoclonal anti-hu 
CD11b-RPE from Dako (Denmark), monoclonal anti-hu CD11c and anti-hu CD11c-A647 and 
mIgG1 from BioLegend (USA), anti-hu CD35-FITC from BD PharMingen (USA), anti-hu 
CD21-PE from Immunotools (Germany), anti-hu iC3b from Quidel (USA). Biotinilated anti-
hu-CD11c and FcR blocking was purchased from Miltenyi Biotec (Germany). The CD11b 
ligand bindig site specific monoclonal antibody TMG6-5 (mIgG1) was kindly donated by 
István Andó, BRC, Szeged, Hungary 
 
Generation of human MDCs 
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Monocytes were isolated from buffy coat obtained from healthy donors and provided 
by the Hungarian National Blood Transfusion Service by magnetic separation of the CD14+ 
monocytes from PBMC or by adherence to gelatin as previously described (Sandor et al., 
2009). Informed consent was provided for the use of blood samples according to the 
Declaration of Helsinki. Cells were cultivated in CellGro serum-free medium supplemented 
with 100 ng/mL rHu GM-CSF and 15 ng/mL rHu IL-4. 
On day five CD14- immature MDCs (imMDCs) were washed and treated with 50 
µg/ml iC3b or with 10 g/ml CD11b specific mAb TMG6-5, for 30 minutes at 37oC. As 
control an isotype-matched antibody was used. After incubation cells were washed 
extensively and cultured in fresh medium supplemented with cytokines for additional 2 days. 
For control samples imMDCs were left untreated. To generate maMDCs, cells were 
resuspended in serum-free medium containing 1 µg/ml LPS. Phenotypical (flow cytometry) 
and functional (MLR, cytokine measurement) studies were carried out at day seven. 
 
Monitoring DC maturation 
The maturation of MDCs was assessed by monitoring the expression of the following 
cell membrane molecules: MHCII, CD40 and mannose receptor (MR). To detect these 
markers cells were stained with the relevant antibodies and analyzed by cytofluorimetry. 
 
Flow cytometry 
For the phenotypic analyses, DCs were incubated with the indicated antibodies for 20 
minutes at 4°C according to the manufacturer’s instruction, and then washed twice in FACS 
buffer (PBS, 1% FCS, 0.1% Na-azide). Isotype-matched antibodies were used as control in 
each case. For intracellular staining cells were fixed in PBS containing 2% formaldehyde and 
permeabilized by 0.2% saponine in the same buffer. Intracellular staining was performed the 
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same way as described for extracellular staining. Samples were analysed using a 
FACSCalibur or FACSAriaIII flow cytometer employing CellQuestPro (Becton Dickinson) 
or FACS Diva software for data aquisition and FCS Express software for data analysis. 
Results are expressed as ΔMFI calculated as follows: (MFIsample – MFIisotype control)/ MFIisotype 
control. 
 
Confocal laser scanning microscopy 
Cells were treated with 50 µg/ml iC3b for 1 hour at 37oC, then fixed, permeabilized 
and stained with anti-iC3b antibody. For visualization a secondary anti-mouseAlexa488 
antibody was applied. Double staining of cell bound iC3b and CD11b or CD11c was 
performed by using anti-iC3b followed by anti-mouseAlexa488, anti-CD11b-biotin followed 
by strepatvidineAlexa647 or anti-CD11c biotin followed by strepatvidineAlexa647, 
respectively. To follow internalization, CD11b was labeled using biotinylated anti-CD11b and 
streptavidine-Alexa546, while CD11c was visualized using anti-CD11c-Alexa647. After these 
staining steps iC3b opsonized Staphylococcus aureus was added to the cells for 1 hour. 
Labeling the receptors prior phagocytosis was necessary because the epitopes of CD11b and 
CD11c recognized by the antibodies are lost upon fixation. The antibodies were tested for 
interference with iC3b binding, and were found negative. Samples were analyzed by an 
Olympus IX81 confocal microscope applying Fluowiev500 confocal workstation.  
 
MLR studies 
MDCs treated as described above were transferred to 96 well plates at day seven and 
further cultured with allogeneic T cells at a DC:T cell ratio of 1:5. T lymphocytes were 
labeled with 0.5 µM CFSE prior to use. After 4 days of coculturing, the proliferation of T 
cells was assessed by analyzing CFSE staining of CD4-Alexa647 labelled cells by 
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cytofluorimetry. MFI+/- SD of the dividing cells is calculated from three independent 
experiments.  
 
Cytokine measurements 
The culture supernatants of MDCs were analyzed 24 hours after the various 
treatments. Measurements for IL-6 and TNF-α were carried out using the R&D duoset 
sandwich ELISA system, while IL-8 production was assesed using the BenderMedsystem 
Instant ELISA kit. Data are presented as mean +/- SD of three independent experiments. 
 
Phagocytosis of opsonized yeast (Saccharomyces cerevisiae), Staphylococcus aureus 
and sheep red blood cells (SRBC) 
Staphylococcus aureus bacteria were kindly provided by Department of Microbiology 
at Eötvös Loránd University. Yeast and bacteria were heat-killed and labelled with FITC 
according to the manufacturer’s (Molecular probes) instructions. For testing the phagocytic 
capacity of imMDCs, yeast and Staphylococcus were opsonized with normal human serum 
for 1 hour at 37oC, then washed extensively and offered to the cells under different conditions. 
To generate S.aureus that is opsonized only with IgG but not complement, bacteria were 
incubated in heat inactivated (HI) serum for 1 hour at 37oC. In some control experiments non-
opsonized yeast and bacteria were also used. In blocking experiments the anti-CD11b or anti-
CD11c antibodies were used at 100 µg/ml concentration and the human FcR blocking 
Miltenyi reagent was employed according to the manufacturers instructions. ImMDCs were 
incubated with opsonized yeast particles at a DC:yeast ratio of 1:5 for 2 hours, or with 
Staphylococcus aureus at 200 μg/ml concentration for 2 hours in a CO2 incubator. The amount 
of the ingested particles were determined by cytofluorimetric analysis using trypane blue for 
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quenching surface bound particles, or by determining the phagocytic index using an 
invertoscope. Data are presented as mean +/- SD of three independent experiments. 
 
RNA silencing 
RNA silencing was performed according to the method of Prechtel (Prechtel et al., 
2007). We used commercially available predesigned Qiagen (Germany) AllStar Negative 
control siRNA and Qiagen Genome Wide predesigned siRNA for CD11c (Hs_ITGAX_6) and 
CD11b (Hs_ITGAM_5). Cells were transfected on day0 and day3 of differentiation with 
20µg siRNA to generate CD11c silenced, CD11b silenced or negative control silenced MDCs 
at day5. The expression of CD11c and CD11b was analyzed on day5 by cytofluorimetry and 
subsequent experiments were carried out on the same day. 
 
Internalization of cell-bound iC3b and CR3 
To follow the fate of cell-bound iC3b-fragments, MDCs were incubated with 50 µg/ml 
iC3b for 30 minutes at 4oC. To test the integrins’ activation state iC3b binding was also 
measured in the presence of 5mM Mg++ (Varga et al., 2007), which is known to induce the 
active conformational state (data not shown). After removing unbound iC3b by washing, the 
cells were kept in medium at 37oC in a CO2 incubator for the indicated time periods. Similar 
treatment was applied using TMG6-5 antibody when the motion of CR3 was studied. MDCs 
were treated with the antibody at 10 µg/ml for 30 min on ice to prevent internalization, then 
washed and incubated at 37oC for the indicated time periods. After fixation, the cells were 
stained for residual surface-bound iC3b and CR3 and analyzed by flowcytometry.  
 
Statistics 
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Student's t-test was performed with GraphPad software; p<0.05 was considered 
significant. 
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Results 
 
1. Expression of CR1 (CD35), CR2 (CD21), CR3 (CD11b/CD18) and CR4 
(CD11c/CD18) on human MDCs 
 Previously we demonstrated that MDCs – similarly to macrophages and B cells - are 
able to fix C3b fragments covalently on their cell surface which enhance the antigen 
presenting capacity of these cells (Kerekes et al., 1998; Papp et al., 2008; Sandor et al., 2009). 
Regarding the expression of complement receptors on DCs, so far only CR3 and CR4 have 
been investigated on MDCs (Kacani et al., 1998; Pickl et al., 1996), but not CR1 (CD35) and 
CR2 (CD21). Thus, we set out to analyze the expression of various complement receptors and 
compared the appearance of CR1, CR2, CR3 and CR4 on immature and mature MDCs. We 
found that imMDCs express very small amounts of CR1, which is completely downregulated 
upon maturation (Figure 1A). In contrast to this, we could detect no CR2 expression either on 
imMDCs or on maMDCs (Figure 1B). Analyzing CD11b and CD11c we found that both 
integrins are expressed constitutively on MDCs (Figure 1C and 1D). During LPS-induced 
maturation of the cells, CR3 was found slightly downregulated in contrast to CR4, which was 
significantly (p=0,018) upregulated (Figure1C, 1D, 1E).  Although the absolute number of 
CR3 and CR4 showed high individual variability, the change in their expression during the 
differentiation was always significant (Figure 1E). As shown in the figure, the expression of 
CD11b decreases to 65%, whereas that of CD11c increases to more than 200% on maMDCs 
compared to imMDCs (Figure 1E). 
 
2. Binding and uptake of iC3b and iC3b-opsonized particles by imMDCs 
Integrins are known to require activation for ligand-binding (Abram and Lowell, 
2009), therefore we tested the cells’ capacity to bind ligands via CR3 and CR4. ImMDCs 
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were incubated with iC3b, the natural ligand of both CR3 and CR4, at 4oC for 30 minutes, 
than binding was assessed using Alexa488 labeled antibody. As shown in Figure 2A, in the 
beginning of the measurement (i.e. at 0 min) we detected strong iC3b deposition on the 
surface of the cells. Since Mg++ is known to initiate the activation of integrins (Varga et al., 
2007), we performed the above experiment on Mg++ pretreated MDCs as described in the 
section of Materials and Methods. We found that this treatment did not enhance the binding of 
the ligand, suggesting that both CR3 and CR4 are already in an active conformation in the cell 
membrane (data not shown). 
Next we analyzed the fate of receptor bound iC3b. To this end the cells were treated 
with iC3b at 4oC followed by incubation at 37oC to allow internalization, as described in 
Materials and methods. Analyzing cell-bound iC3b after 2 hours we found a significant 
(p=0,0039) decrease of the ligand on the cell surface, which was further diminished by 48 hrs  
(Figure 2A). To investigate whether the cells internalize the ligand or shed it from the cell 
membrane, we analyzed the cells by confocal microscopy. Our data show that after 2 hours 
surface-bound iC3b is engulfed by the cells. The distribution of C3-fragments is not even 
neither on the cell membrane nor inside the cells; staining appears in small patches (Figure 
2B). We also tested whether both CR3 and CR4 are able to bind the ligand. We treated the 
cells with iC3b at 4oC for 30 minutes and then detected cell-bound iC3b along with CD11b or 
CD11c. As shown in Figure 2C  the ligand colocalizes with both CD11b and CD11c. 
Since we observed a strong expression of both CR3 (CD11b/CD18) and CR4 
(CD11c/CD18) by MDCs (Figure 1C and 1D.) we aimed to clarify the role of these receptors 
in the phagocytosis of iC3b opsonized particles. First we tested the binding and uptake of 
iC3b opsonized yeast (Saccharomyces cerevisiae) and iC3b opsonized bacteria 
(Staphylococcus aureus). These two types of microbes are known to fix C3-fragments on their 
surface mainly as iC3b (Turner et al., 1986). Figure 2D shows the phagocytosis of opsonized 
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yeast by imMDCs at 4oC and 37oC, and Figure 2E demonstrates the binding of iC3b 
opsonized Staphylococcus aureus to imMDCs under the same conditions.  
 
3. CR3 has a dominant role over CR4 in the uptake of iC3b opsonized yeast and bacteria 
Although it has not been clearly demonstrated so far, it is generally thought, that the 
functions of CR3 and CR4 are very similar, since both take part in the binding and uptake of 
iC3b opsonized particles. To clarify whether the role of these receptors is indeed identical, we 
analyzed the process of phagocytosis of iC3b opsonized yeast particles and Staphylococcus 
aureus using imMDCs pretreated with anti-CD11b and anti-CD11c antibody, respectively. 
Our results show, that treatment with anti-CD11b significantly decreased the phagocytic 
capacity of imMDC compared to the control sample, where isotype-matched antibody was 
used. This result was independent of the particle used, since the uptake of both the iC3b-
opsonized yeast and bacteria was inhibited in a similar manner (Figure 3A, 3B). Interestingly, 
incubation with anti-CD11c did not affect the uptake of the opsonized microorganisms by 
imMDCs (Figure 3A, 3B), in contrast to anti-CD11b.  
It is known that Fc receptors also mediate phagocytosis and work in cooperation with 
complement receptors. To test whether blocking CD11b affects the phagocytosis mediated by 
FcRs or pattern recognition receptors we also assessed the uptake of non-opsonized bacteria 
and bacteria treated by heat inactivated (HI) serum. In this latter case IgG may bind to the 
bacteria, thus FcR.mediated phagocytosis can take place  As shown in Figure 3C only 12% of 
imMDCs phagocytosed non-opsonized bacteria and opsonization with HI serum enhanced the 
percentage of bacteria positive cells only slightly (up to 17%). In contrast to this, when S. 
aureus was opsonized by normal serum where complement activation and iC3b deposition 
occurs, 66% of the cells took up the bacteria (Figure 3C). Although these data show that the 
possible opsonization by IgG  alone does not cause a strong enhancement,  we analyzed 
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whether CD11b or CD11c plays a role in the uptake of non-opsonized or HI serum opsonized 
microorganisms. To this end we blocked the complement receptors by antibodies. Our results 
show that neither the possible pattern recognition receptor mediated uptake (Figure 3D) nor 
the IgG mediated phagocytosis (Figure 3E) is influenced by CD11b or CD11c. To further 
prove that under our experimental conditions the Fc receptors do not play a major role in the 
uptake of iC3b opsonized bacteria, we assessed phagocytosis in the presence or absence of 
FcR blocking, and found no difference (Figure 3F).  
These results were further strengthened by our experiments where we employed 
CD11b and CD11c silenced MDCs. We treated MDCs during their he differentiation with 
CD11b or CD11c specific siRNA fragments and thus obtained imMDCs expressing 
significantly lower level of CR3 (CD11b, Figure 4A) or CR4(CD11c, Figure 4B) than the 
control siRNA treated cells. Silencing efficiency was approximately 70%. Using the CD11c 
and CD11b silenced cells for phagocytosis we confirmed our findings obtained by blocking 
the receptors with antibodies; namely CD11c downregulation had no effect on phagocytosis.  
(Figure 4C, 4D), while CD11b silenced MDCs exhibited significantly lower capacity to 
uptake the iC3b opsonized yeast (Figure 4E) or bacteria (Figure 4F). To exclude that CD11b 
silencing might change the general phagocytic capacity of the MDCs we also determined how 
the control and the CD11b silenced MDCs internalize non-opsonized yeast (Figure 4G) and 
bacteria (Figure 4H), and found no difference. 
 
4. The fate of CR3 and CR4 during uptake of iC3b opsonized yeast and bacteria 
 To analyze the iC3b-mediated phagocytosis in more detail, and to determine the 
participation of CR3 and CR4 in the process, we monitored the route of iC3b opsonized 
Staphylococcus aureus by confocal microscopy. Figure 5A-5D shows the distribution of  
CD11b (red) and CD11c (blue) on imMDCs, when determined separately, in the absent of the 
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ligand. The yellow lines that crosses two adjacent cells are used as markers, along which the 
fluorescence intensity of the two dyes has been calculated and is represented in the histogram 
(Figure 5D). These data clearly demonstrate that the two integrins, CR3 and CR4 colocalize 
in the cell membrane of imMDCs. Figure 5E-5H shows the results of a similar measurement, 
when imMDCs were incubated with 200µg/ml iC3b opsonized Staphylococcus aureus after 
labeling of the receptors. In this case CD11b is almost completely transferred into the 
cytoplasm, thus it is absent from the cell membrane, whereas CD11c remains mainly there. 
This is clearly seen in Figure 5H where CD11b intensity is high only inside the cells and in 
the region of the cell membrane where two cells are in contact.  
To confirm our data obtained by confocal microscopy we measured the cell surface 
expression of CD11b and CD11c before and after phagocytosis of opsonized S. aureus also by 
flowcytometry. We stained the cells for CD11b and CD11c in the absence of the ligand and 
also after iC3b opsonized bacteria were phagocytosed. Figure 5I shows that the expression of 
CD11b on the cell membrane is significantly reduced after phagocytosis, but that of CD11c is 
not, supporting our results obtained by confocal microscopy. The virtual contradiction 
between data on Figure 5E where CD11b is almost completely missing from the cell surface  
and data on Figure 5I where CD11b is present still in substantial amounts even after 
phagocytosis can be explained by the fact, that CD11b recycles very quickly between 
intracellular pools and the cell membrane (Bretscher, 1992). Therefore in cytofluorymetric 
measuerements we can only stain those receptors that come to the cell surface during 
phagocytosis (as seen in Figure 5I), while in the microscopic measurements CD11b molecules 
disappear, (Fig. 5E) since we can label them only prior to phagocytosis. These data suggest 
that although CD11c may also participate in the process of the complement-dependent 
phagocytosis (Figure 5H), its role is not essential.  
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To further analyze the function of CR3 (CD11b/CD18), we used the monoclonal 
antibody TMG6-5, which interacts specifically with the ligand binding site of CD11b.  First, 
we analyzed whether the antibody behaves similarly to the natural ligand. We treated the cells 
with TMG6-5 at 10µg/ml, and followed its internalization by cytofluorimetry at the indicated 
periods of time. As shown in Figure 5J, CD11b molecules crosslinked by the TMG6-5 mAb 
were internalized similarly to the natural ligand. Based on these data, in our next experiments 
we used the TMG6-5 antibody to analyze the function of CD11b on imMDCs. 
 
5. CR3 crosslinking does not induce the maturation of MDC  
We have shown that both CR3 and CR4 are present in an active conformation on the 
surface of imMDCs ready to bind iC3b, their natural ligand,. As we found that CD11b is the 
dominant receptor in the iC3b mediated phagocytosis, we wanted to clarify whether this 
interaction transduces activating signals to the MDCs. To this end we treated imMDCs either 
with iC3b or the TMG6-5 antibody, which is specific to the ligand binding site of CD11b  The 
advantage of using iC3b is that the complement receptors are triggered by their physiological 
ligand, but the disadvantage is that both CD11b and CD11c are stimulated simultaneously.  
ImMDCs were treated with the different stimuli for 30 minutes at 37oC, then washed and 
cultured for additional two days. The activation state of MDCs was estimated by 
flowcytometry, by assessing the expression of MHCII, MR, CD40, CD83 and CD86 
molecules. Data summarized in Table1 demonstrate that stimulation with iC3b, anti-CD11b 
(TMG6-5) or the isotype matched control did not cause significant alteration in the phenotype 
of imMDCs. This indicates that the previously reported tolerogenic effect (Birdsall et al., 
2005; Ehirchiou et al., 2007; Morelli et al., 2003; Schmidt et al., 2006; Veldhoen, 2007; 
Verbovetski et al., 2002) is not mediated by CD11b. As positive control, LPS stimulated 
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maMDCs were used, which highly expressed MHCII, CD40, CD83 and CD86 while the level 
of MR was decreased (Table1.). 
 
6. Engagement of CR3 has no effect on the capacity of MDCs to trigger allogenic T cell 
activation and cytokine production  
To find out whether certain functions of MDCs can be regulated via CD11b, we analyzed the 
allogenic T cell stimulatory capacity and cytokine production of iC3b and TMG6-5 treated 
cells. ImMDCs were treated with iC3b or with the binding-site specific anti-CD11b (TMG6-
5) mAb for two days, then cocultured with allogenic T cells at DC:T=1:5 ratio for 4 days. 
Proliferation of CFSE and CD4 labeled T cells was measured by flowcytometry. As it is 
shown in Figure 6A neither iC3b, nor anti-CD11b affected the T cell stimulatory capacity of 
MDCs. We also measured the amount of IL-8, IL-6 and TNF-α from the supernatants of 
differently treated MDCs (Figure 6B, 6C, 6D). However, as shown in Figure 6B, 6C, and 6D, 
engagement of CR3 did not increase significantly the production of none of these cytokines. 
In both set of experiments LPS-matured maMDCs were used as positive control, which are 
known to stimulate allogeneic T cells and to produce high amounts of the measured cytokines. 
(Figure 6B, 6C, 6D). 
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Discussion 
Constantly increasing data provide evidence that certain complement activation 
products strongly influence adaptive immune responses (Carroll, 2004; Kemper and Atkinson, 
2007, Török et al., 2012). It has been also suggested that the uptake of complement opsonized 
particles via complement receptors C1qR, CR3, CR4 might play an important role in the 
maintenance of peripheral tolerance (Morelli et al., 2003; Nauta et al., 2004; Nauta et al., 
2002; Schmidt et al., 2006; Skoberne et al., 2006; Sohn et al., 2003; Verbovetski et al., 2002). 
In this process DCs are of prominent importance. Regarding receptors for various C3-derived 
fragments, MDCs are reported to express iC3b-binding CR3 and CR4, while CR1 (CD35) and 
CR2 (CD21), interacting with C3b and C3d fragments can not be detected on the surface of 
these cell types. (Pickl et al., 1998,Li et al., 2003,Bajtay et al. 2004). Integrins – including 
CR3 and CR4 - are known to be involved in various cellular processes associated with 
cytoskeletal remodeling, which are necessary for adherence and phagocytosis. It has been 
demonstrated that ligation of CR3 on mouse DCs increases the appearance of surface MHC 
and costimulatory molecules, and inhibits the release of inflammatory cytokines. This 
suggests that CR3 may provide a non-danger signal that suppresses the stimulatory capacity 
of DCs (Behrens et al., 2007). 
β2 integrins are also known to mediate phagocytosis, which is crucial for the removal 
of antigens and apoptotic cells.  The importance of these molecules in anti-microbial defense 
is confirmed by the fact that patients with leukocyte adhesion deficiency type I (LAD I) 
syndrome lacking functional β2 integrins are highly susceptible to bacterial infections 
(Bunting et al., 2002; Gresham et al., 1991). Recently MacPherson and colleagues found that 
a mutation in the CD11b gene results in the lack of cell adhesion via ICAMs or iC3b. These 
deficiencies may ultimately lead to detrimental effects on the immune system and contribute 
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to the development of certain diseases, such as systemic lupus erythematosus (MacPherson et 
al., 2011).  
 While CD11c is a widely accepted marker of myeloid cells, the proper function of 
CD11c/CD18 is not well characterized yet, in contrast to CD11b/CD18, which is known for 
long as a potent phagocytic receptor.  Dissection of the function of CR3 and CR4 is hampered 
by the fact that their ligand specificity is identical and the extracellular domains of these 
molecules share 87% homology. Many data suggest however, that beside their overlapping 
functions, CR3 and CR4 may also have distinct functions. Ligand binding to integrins induces 
conformational changes and is involved in outside-in signaling, which can affect a variety of 
cellular functions such as apoptosis, cytotoxicity, proliferation, cytokine production, antigen 
presentation, and gene activation (Abram and Lowell, 2009; Berton and Lowell, 1999).  
In our present study we show that ligation of CD11b with its natural ligand, iC3b or by 
specific antibody induce receptor internalization within 10 minutes (Figure 1). This 
interaction however does not result in any significant change in the phenotype of the MDCs 
(Table1). This is an interesting finding, since according to available data, CR3 can be 
considered rather an inhibitory complement receptor, that mediates the induction of tolerance 
(Behrens et al., 2007; Ehirchiou et al., 2007; Sohn et al., 2003; Varga et al., 2007; Veldhoen, 
2007; Wagner et al., 2001). In our system we found that the inhibition of CD11b significantly 
decreases the uptake of iC3b opsonized yeast and Staphylococcus aureus particles by 
imMDCs, while the inhibition of CD11c had no significant effect on this process (Figure 3). 
This is in a good agreement with the results of Georgakopoulos et al, who demonstrated that 
CD11c/CD18 was less susceptible to activation than the other β2-integrins, suggesting that 
CR4 is more tightly regulated. Although in these experiments CD11c was also shown to be 
involved in the adhesion of cultured monocytes, the role of CD11b proved to be more 
important to induce cytoskeletal changes leading to increased spreading and formation of 
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actin foci, suggesting a pivotal role of CD11b in the cells’ responses (Georgakopoulos et al., 
2008).  
Regarding the function of CR3 an other notable finding has also been published 
earlier, namely that functionally distinct populations of CD11b/CD18 molecules are present 
on monocytes and neuotrophil granulocytes; one of them is involved in the binding of iC3b 
opsonized particles while the other takes part in the process of phagocytosis mediated via 
several different receptors (Graham et al., 1989). In the present study we demonstrate that 
while both CR3 and CR4 are involved in the uptake of complement opsonized particles, 
binding to CD11c alone is not sufficient to initiate phagocytosis. We clearly show that CD11b 
has a primary role in this process (Figure 3, 4, 5). 
Complement component C3 is an acute phase protein, the activation of which is an 
indicator of the actual physiological state of the body. It is well-known that inflammatory 
stimuli cause an increase in the amounts of C3 activation products in various body fluids. 
Earlier we have shown that MDCs – in contrast to macrophages - do not secrete C3 protein, 
but are able to fix freshly generated C3b fragments covalently (Sandor et al., 2009).This 
interaction directs MDCs to differentiate into mature DCs and to stimulate allogenic T cell 
proliferation.  Our present work demonstrates that the pathogen bound iC3b interacting with 
CR3 and CR4 on MDCs act in a different manner. We show that in contrast to the covalently 
fixed C3-fragments, iC3b bound to CR3 and CR4 stimulate neither the differentiation of 
MDCs, nor the production of inflammatory cytokines, furthermore the capacity of MDCs to 
stimulate allogeneic T-cells  is also not influenced by iC3b. These results together with our 
previous ones point to the importance of the actual microenvironment of the maturing DCs. 
Namely, the functional consequences are completely different if the cells have the possibility 
to fix nascent C3b via their C3b-acceptor sites, or if they interact with opsonized antigens 
bearing iC3b. We assume that in the former case complement producing macrophages deliver 
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native C3 in the close vicinity of DCs (e.g. in the lymph nodes) where it is cleaved by cell 
membrane proteases (Erdei et al., 1992; Fabry et al., 1985; Gergely et al., 1985; Kerekes et 
al., 1998; Maison et al., 1989). In the case however, when maturing DCs get into contact with 
iC3b-opsonized particles, complement receptors CR3 and CR4 take action and the outcome 
might be profoundly different. Activation via CR3 does not induce differentiation of DCs but 
the contribution of these receptors is crucial in the uptake of complement opsonized 
pathogens. On the other hand CR4 alone is unable to initiate phagocytosis. Thus it seems that 
there is a complex interplay between the various complement binding structures of DCs, 
which decisively influences the actual response of the cells. Further studies revealing the 
intricacy of these interactions will help to clarify the exact molecular mechanisms and the 
specific signaling processes mediated by CD11b and CD11c.  
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Figure legends 
Figure 1. Expression of CD35, CD21, CD11b and CD11c on the surface of im- and 
maMDCs  
Expression of CD35 (CR1) (A), CD21 (CR2) (B), CD11b (CR3) (C) and CD11c (CR4) (D) 
was measured on imMDCs and maMDCs using specific antibodies. MaMDCs were generated 
by stimulating the imMDCs with 1 µg/ml LPS for 2 days. Black lined histogram shows 
receptor expression on imMDCs, gray lined histogram on maMDCs, while the filled grey 
histograms represent the  isotype control. One representative experiment out of five indepent 
is shown. E: Maturation downregulates CD11b expression while upregulates CD11c 
expression on MDCs, this is expressed as ΔMFI CD11b on imMDCs/ ΔMFI CD11b on 
maMDCs and ΔMFI CD11c on imMDCs/ ΔMFI CD11c on maMDCs. Results are mean+/- 
SD of five independent expreiments. 
Figure 2. Binding of iC3b and iC3b opsonized particles to imMDCs 
A: ImMDCs were treated with 50 µg/ml iC3b at 4oC for 30 minutes, washed and further 
incubated at 37oC. Cells were analyzed for surface bound iC3b using anti-iC3b+anti-mouse 
IgG-Alexa488 at the indicated timepoints using cytofluorimetry. Mean ΔMFI+/-SD of iC3b 
staining of three indepent experiments is shown, ***p=0,0004. B: Confocal microscopic 
picture of imMDCs treated with 50 µg/ml iC3b at 37oC for 2 hours, fixed, permeabilized and 
stained with anti-iC3b+anti-mouse IgG-Alexa488. 60x magnification with further digital 
magnification was used. One representative experiment out of five indepent is shown. C: 
ImMDCs were treated with 50 µg/ml iC3b at 4oC for 30 minutes, washed and double stained 
for iC3b and CD11b (upper panel) or CD11c (lower panel) using  anti-iC3b+anti-mouse IgG-
Alexa488 and biotin conjugated anti-CD11b (upper panel) or biotin conjugated anti-CD11c 
(lower panel) antibody + streptavidine-Alexa647. Upper panel shows iC3b in green and 
CD11b in blue and merged. Lower panel shows iC3b in green and CD11c in blue and merged. 
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60x magnification with further digital magnification was used. One representative experiment 
out of three is shown. D: imMDCs were coincubated with opsonized yeast at DC:yeast=1:5 
ratio for 2 hours at 4oC or 37oC and phagocytic index was determined. Phagocytic index using 
non-opsonized yeast is substracted in each case. Values are calculated as mean+/-SD of three 
independent experiments. E: ImMDCs were incubated with FITC labeled 200 µg/ml 
opsonized Staphylococcus aureus at 4oC or 37oC for 2 hours and analyzed for phagocytosed 
bacteria using cytofluorimetry. Results using non-opsonized bacteria are substracted in each 
case. Values are calculated as mean+/-SD of three independent experiments. 
Figure 3. CR3 has a dominant role over CR4 in the uptake of iC3b opsonized yeast and 
bacteria 
ImMDCs were pretreated with anti-CD11b, anti-CD11c or isotype matched control antibody 
at 100µg/ml, washed and were incubated with iC3b opsonized yeast particles for 1 hour at 
37oC (A). Phagocytic index was determined. Data shown are mean values calculated from 
four independent experiments +/- standard deviation. *p=0,0329. B: ImMDCs were pretreated 
the same way as in A and were incubated with 200 µg/ml iC3b opsonized FITC labeled 
Staphylococcus aureus and analyzed by cytofluorimetry. Data shown are mean values 
calculated from four independent experiments +/- standard deviation. *p=0,0387. C: 
Phagocytosis of 200 µg/ml non-opsonized, heat-inactivated serum opsonized and normal 
human serum opsonized FITC labeled Staphylococcus aureus by imMDCs was aalyzed by 
flow cytometry. Cells were incubated with the bacteria for 1 hour, washed and analyzed for 
FITC positivity. In the case of non-opsonized and heat-inactivated serum opsonized bacteria 
only 12% and 17% of MDCs were able to phagocytose. When bacteria was opsnoized by 
normal human sera, 66% of MDCs phagocytosed. One representative measurement out of five 
is shown. Black lined histogram represents MDCs that were coincubated with bacteria, filled 
gray histogram represents autofluorescence. D-E: ImMDCs were pretreaed as in A and were 
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incubated with 200 µg/ml non-opsonized FITC labeled Staphylococcus aureus (D) or  200 
µg/ml heat-inactivated serum opsonized FITC labeled Staphylococcus aureus (E) and 
analyzed by cytofluorimetry. Data shown are mean values calculated from four independent 
experiments +/- standard deviation. F: ImMDCs were left untreated (control) or pretreated 
with Fc receptor blocking reagent and their capacity to phagocytose 200 µg/ml iC3b 
opsonized FITC labeled Staphylococcus aureus was analyzed by  +/- standard deviation. 
Figure 4. The dominant role of CD11b in the uptake of iC3b opsonized yeast and 
bacteria is supported by RNA silencing. 
To analyze the role of CD11c in the phagocytosis of iC3b opsonized particles, CD11c and 
CD11b expression of imMDCs was downregulated using RNA silencing method. A: 
Cytofluorimetric analysis of a representative CD11b silencing experiment is shown. Filled 
grey histogram represents isotype control, black line shows CD11b expression on negative 
control siRNA transfected cells, grey line shows CD11b expression on CD11b targeted 
siRNA transfected cells. The average value of receptor downregulation was 70%. B: 
Cytofluorimetric analysis of a representative CD11c silencing experiment is shown. Filled 
grey histogram represents isotype control, black line shows CD11c expression on negative 
control siRNA transfected cells, grey line shows CD11c expression on CD11c targeted siRNA 
transfected cells. The average value of receptor downregulation was 70%. C-D: Phagocytosis 
of iC3b opsonized yeast (C) and iC3b opsonized bacteria (D) by control siRNA transfected 
and CD11c silenced imMDCs. Phagocytosis was measured as mentioned in Figure 2. 
Represented data are mean values calculated from five independent experiments +/- standard 
deviation. E-F: Phagocytosis of iC3b opsonized yeast (E) and iC3b opsonized bacteria (F) by 
control siRNA transfected and CD11b silenced imMDCs. Phagocytosis was measured as 
mentioned in Figure 2. Represented data are mean values calculated from five independent 
experiments +/- standard deviation, p=0,0065 for phagocytosis of yeast (E) and p=0,0012 for 
34 
 
phagocytosis of bacteria (F). G-H: Phagocytosis of non-opsonized yeast (G) and non-
opsonized bacteria (H) by control siRNA transfected and CD11b silenced imMDCs. 
Phagocytosis was measured as mentioned in Figure 2. Represented data are mean values 
calculated from five independent experiments +/- standard deviation.  
Figure 5. Route of CR3 and CR4 during uptake of iC3b opsonized yeast and bacteria 
A-D: ImMDCs were labeled for CD11b (red) and CD11c (blue) using anti-CD11b biotin + 
streptavidin-Alexa546 and anti-CD11c-Alexa647. A shows CD11b staining, B shows CD11c 
staining, C shows the two pictures merged. As seen on D that represents the fluorescence 
intensity of the two labeled receptors along the yellow line that crosses two cells, CD11b (red) 
and CD11c (blue) are both present in the cell membrane. Yellow arrows are pointing to the 
cell membrane on the microscopic picture and on the histogram. E-H: ImMDCs were labeled 
the same as in A-D but after staining of the receptors cells were incubated with 200 µg/ml 
iC3b opsonized Staphylococcus aureus. As seen on the pictures (E,G) and the intensity 
histogram (H) CD11b enters the cells, and almost completely disappears from the cell 
membrane, while CD11c mostly stays in the membrane, although some molecule enters the 
cell. Yellow arrows are pointing to the cell membrane on the microscopic picture and on the 
histogram. It is also shown that colocalization of CD11b and CD11c is reduced during 
phagocytosis (G) in contrast to untreated cells (C). I: ImMDCs were analyzed for CD11b and 
CD11c expression before and after phagocytosis of iC3b opsonized Staphylococcus aureus to 
analyze the internalization of CR3 and CR4.  Mean ΔMFI of three independent experiments 
+/-SD is shown, **p=0,0052. J: ImMDCs were treated with TMG6-5 antibody that 
recognizes the iC3b ligand binding site of CD11b at 10 µg/ml concentration for 30 minutes on 
ice (■) to allow binding to CD11b but preventing internalization. Than the cells were washed 
to remove unbound antibodies and transferred to 37oC. Samples were analyzed for the 
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remaining CD11b on cell surface at the indicated timepoints by flow cytometry. Data are 
means of three independent experiments +/-SD.  
Figure 6. Functional effect of CR3 triggering on MDCs. 
A: The differently treated MDCs at day 7 were washed and cocultured for additional 4 days 
with CFSE loaded allogeneic T cells at DC:T cell ratio 1:5. Cell proliferation was assesed by 
determining the CFSE MFI of the dividing anti-CD4-Alexa647 labeled cells. Data represented 
are mean values calculated from five independent experiments +/- standard deviation. 
*p=0,0271. B-D: IL-6, IL-8 and TNF-α concentrations were measured from the differently 
treated cells 24 hour supernatant by ELISA. Data represented are mean values calculated from 
five independent experiments +/- standard deviation. ***p<0,0001. 
 
  imMDC maMDC isotype CD11b iC3b 
MHCII 293.95 +/- 61.08 456.61 +/- 51.35 *** 317.46 +/- 34.53 265.65 +/- 61.2 288.73 +/- 40.23 
MR 44.97 +/- 2.87 32.26 +/- 1.6 *** 44.57 +/- 3.83 45.02 +/- 5.11 45.84 +/- 3.46 
CD40 204.42 +/- 14.18 294.42 +/- 24.84 *** 217.42 +/- 15.79 226.45 +/- 23.18 224.6 +/- 18.61 
CD83 8.10 +/- 0.45 25.93 +/- 2.33 *** 7.53 +/- 0.76 7.25 +/- 0.74 7.08 +/- 0.75 
CD86 50.44 +/- 3.03 138.38 +/- 58.32 ** 49.65 +/- 12.08 47.22 +/- 10.23 39.21 +/- 7.98 
 
Table1. Triggering via CR3 does not affect the phenotype of human MDCs  
ImMDCs on day 5 were treated with iC3b, the iC3b ligand binding site specific anti-CD11b 
antibody and an isotype-matched control antibody, or left untreated. After incubation for 30 
min at 37oC cells were washed and cultured for additional two days. MaMDCs were 
generated by stimulating the imMDCs with LPS. MDCs were analyzed for the expression of 
the indicated markers by cytofluorimetry on day 7. Data presented are mean ΔMFI values 
calculated from five independent experiments, +/- standard deviation. Students’ paired t-test 
was used to compare the effect of the different treatments to untreated control cells 
(imMDCs), Individual p values are as follows: maMDC MHCII: 0,0019; maMDC 
MR:<0,0001; maMDC CD40: 0,0001, maMDC CD83: <0,0001; maMDC CD86: 0,0098. 
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Figure6
  imMDC maMDC isotype CD11b iC3b 
MHCII 293.95 +/- 61.08 456.61 +/- 51.35 *** 317.46 +/- 34.53 265.65 +/- 61.2 288.73 +/- 40.23 
MR 44.97 +/- 2.87 32.26 +/- 1.6 *** 44.57 +/- 3.83 45.02 +/- 5.11 45.84 +/- 3.46 
CD40 204.42 +/- 14.18 294.42 +/- 24.84 *** 217.42 +/- 15.79 226.45 +/- 23.18 224.6 +/- 18.61 
CD83 8.10 +/- 0.45 25.93 +/- 2.33 *** 7.53 +/- 0.76 7.25 +/- 0.74 7.08 +/- 0.75 
CD86 50.44 +/- 3.03 138.38 +/- 58.32 ** 49.65 +/- 12.08 47.22 +/- 10.23 39.21 +/- 7.98 
 
Table1. Triggering via CR3 does not affect the phenotype of human MDCs  
ImMDCs on day 5 were treated with iC3b, the iC3b ligand binding site specific anti-CD11b 
antibody and an isotype-matched control antibody, or left untreated. After incubation for 30 
min at 37oC cells were washed and cultured for additional two days. MaMDCs were 
generated by stimulating the imMDCs with LPS. MDCs were analyzed for the expression of 
the indicated markers by cytofluorimetry on day 7. Data presented are mean ΔMFI values 
calculated from five independent experiments, +/- standard deviation. Students’ paired t-test 
was used to compare the effect of the different treatments to untreated control cells 
(imMDCs), Individual p values are as follows: maMDC MHCII: 0,0019; maMDC 
MR:<0,0001; maMDC CD40: 0,0001, maMDC CD83: <0,0001; maMDC CD86: 0,0098. 
 
